Literature DB >> 23205292

Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer.

Richard L Carpenter1, Hui-Wen Lo.   

Abstract

Entities:  

Year:  2012        PMID： 23205292      PMCID： PMC3506804          DOI： 10.3978/j.issn.2072-1439.2012.10.09

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  29 in total

Review 1.  Non-small cell lung cancer.

Authors:  David S Ettinger; Wallace Akerley; Gerold Bepler; Matthew G Blum; Andrew Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Apar Kishor P Ganti; Ramaswamy Govindan; Frederic W Grannis; Thierry Jahan; Mohammad Jahanzeb; David H Johnson; Anne Kessinger; Ritsuko Komaki; Feng-Ming Kong; Mark G Kris; Lee M Krug; Quynh-Thu Le; Inga T Lennes; Renato Martins; Janis O'Malley; Raymond U Osarogiagbon; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; George R Simon; Scott J Swanson; Douglas E Wood; Stephen C Yang
Journal:  J Natl Compr Canc Netw       Date:  2010-07       Impact factor: 11.908

Review 2.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

3.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

Review 4.  The resurgence of covalent drugs.

Authors:  Juswinder Singh; Russell C Petter; Thomas A Baillie; Adrian Whitty
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 5.  Irreversible protein kinase inhibitors.

Authors:  L Garuti; M Roberti; G Bottegoni
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 6.  Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.

Authors:  Woody Han; Hui-Wen Lo
Journal:  Cancer Lett       Date:  2012-01-17       Impact factor: 8.679

7.  Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.

Authors:  Pasi A Jänne; Xiaofei Wang; Mark A Socinski; Jeffrey Crawford; Thomas E Stinchcombe; Lin Gu; Marzia Capelletti; Martin J Edelman; Miguel A Villalona-Calero; Robert Kratzke; Everett E Vokes; Vincent A Miller
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

8.  Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  Suresh S Ramalingam; Fiona Blackhall; Maciej Krzakowski; Carlos H Barrios; Keunchil Park; Isabel Bover; Dae Seog Heo; Rafael Rosell; Denis C Talbot; Richard Frank; Stephen P Letrent; Ana Ruiz-Garcia; Ian Taylor; Jane Q Liang; Alicyn K Campbell; Joseph O'Connell; Michael Boyer
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

Review 9.  Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

Authors:  Kim-Son H Nguyen; Susumu Kobayashi; Daniel B Costa
Journal:  Clin Lung Cancer       Date:  2009-07       Impact factor: 4.785

10.  A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  Enriqueta Felip; Federico Rojo; Martin Reck; Astrid Heller; Barbara Klughammer; Gemma Sala; Susana Cedres; Sergio Peralta; Heiko Maacke; Dorothee Foernzler; Marta Parera; Joachim Möcks; Cristina Saura; Ulrich Gatzemeier; José Baselga
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531
View more
  5 in total

Review 1.  Lung cancer biomarkers, targeted therapies and clinical assays.

Authors:  Jai N Patel; Jennifer L Ersek; Edward S Kim
Journal:  Transl Lung Cancer Res       Date:  2015-10

2.  Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.

Authors:  Yiming Zhong; Shuai Dong; Ethan Strattan; Li Ren; Jonathan P Butchar; Kelsey Thornton; Anjali Mishra; Pierluigi Porcu; J Michael Bradshaw; Angelina Bisconte; Timothy D Owens; Erik Verner; Ken A Brameld; Jens Oliver Funk; Ronald J Hill; Amy J Johnson; Jason A Dubovsky
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

3.  Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  V Hirsh; N Blais; R Burkes; S Verma; K Croitoru
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

4.  Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket.

Authors:  John D Harling; Angela M Deakin; Sébastien Campos; Rachel Grimley; Laiq Chaudry; Catherine Nye; Oxana Polyakova; Christina M Bessant; Nick Barton; Don Somers; John Barrett; Rebecca H Graves; Laura Hanns; William J Kerr; Roberto Solari
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

Review 5.  Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.

Authors:  Timothy A Yap; Sanjay Popat
Journal:  Pharmgenomics Pers Med       Date:  2014-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.